Background and previous work

1. Treatment of solid tumours remains challenging, possibly due to the tumour suppressive microenvironment. Understanding antigen expression and its influence on adaptive responses is crucial.

Methods

- 

Results

- NY-ESO-1 and LAGE-1a expression varies among sarcoma types. Unlike sarcoma types and multiple sarcoma subtypes, the expression level of NY-ESO-1 and LAGE-1a was not significantly different, except for long sarcoma (LSO) that varied significantly between sarcoma types and multiple sarcoma subtypes. The expression level of NY-ESO-1 and LAGE-1a was not significantly different, except for long sarcoma (LSO) that varied significantly between sarcoma types and multiple sarcoma subtypes.

Alme: NY-ESO-1 and LAGE-1a expression varies among sarcoma types. Unlike sarcoma types, the expression level of NY-ESO-1 and LAGE-1a was not significantly different, except for long sarcoma (LSO) that varied significantly between sarcoma types and multiple sarcoma subtypes. The expression level of NY-ESO-1 and LAGE-1a was not significantly different, except for long sarcoma (LSO) that varied significantly between sarcoma types and multiple sarcoma subtypes.

Conflicts of interest: All authors have completed the统一on of interests’ statement and declare no competing interests.

Conclusion

- GSK3377794 shows promise in enhancing tumour cell expression of NY-ESO-1 and LAGE-1a, enabling the development of novel immunotherapies targeting these antigens.